SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon reports more than double revenue from Biologics in Q2FY19

26 Oct 2018 Evaluate

Biocon has reported more than double revenue from the Biologics segment, comprising Novel Biologics and Biosimilars, at Rs 367 crore in Q2FY19. The growth was driven by the commercial launch of biosimilar Pegfilgrastim in the US and strong sales of Insulins as well as biosimilar MAbs in key emerging markets.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

383.50 2.75 (0.72%)
07-May-2026 15:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1835.25
Dr. Reddys Lab 1306.55
Cipla 1362.95
Zydus Lifesciences 941.35
Lupin 2455.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×